Veracyte Announces New Clinical Data Showing First-Ever Noninvasive Nasal Swab Test Can Enable Early Lung Cancer Detection and Diagnosis Data presented today at CHEST 2019 Annual Meeting; Company plans to begin making test available in early 2021 Conference call and webcast today at 5:00 p.m. ET to review third quarter 2019 Financial results and the new nasal swab test data Veracyte, Inc. (Nasdaq: VCYT) today announced preliminary clinical data showing that the companys noninvasive nasal swab test - the first of its kind - can enable early lung cancer detection and diagnosis so that more lives can be saved. The new findings specifically show that the novel genomic test can accurately classify lung cancer risk in patients with lung nodules so that these patients can obtain the prompt diagnosis and potential treatment they need or may be monitored noninvasively. The findings will be presented today at the annual meeting of the American College of Chest Physicians® (CHEST) in New Orleans. Early ...
A look at the following clinical trial: Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours
A look at the following clinical trial: Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable Non-Small Cell Lung Cancer (NSCLC) or Metastatic Lung Tumours
Could the Neutrophil to Lymphocyte Ratio be a Poor Prognostic Factor for Non Small Cell Lung Cancers? Lung cancer;neutrophil to lymphocyte ratio;prognostic factors;C reactive protein; Background: Although many prognostic factors have been identified for lung cancers, new ones are needed to determine the course of the disease. Recently, a high neutrophil to lymphocyte ratio (NLR) prior to surgery or treatment has been shown to be an indicator of prognosis for cancer. The aim of this study was to investigate the value of NLR as a prognostic factor and the correlation between NLR and other probable clinical prognostic factors in non small cell lung cancer patients prior to treatment. Materials and Methods: Data of patients who were diagnosed with non-small cell lung cancer in our institution were retrospectively reviewed. Demographic and clinicopathologic characteristics were recorded. NLR was calculated before the application of any treatment. Results: A total of 299 patients, 270 (90%) males and 29 (10
Since this squamous cell lung cancer is being considered as destructive neoplasm in lungs, additional care is paid towards incorporating the effective supportive therapy in the regular anti cancerous therapy, involving multi drug combinations. The supportive therapy may include usage of suitable corticosteroid drugs like prednisolone in a routine form and it is noteworthy to mention that in some patients, a repository form of this corticosteroid may also be used to fulfill the need of constant delivery.. Surgery is also being considered as therapy in cases of squamous cell lung cancer. But, if the spread of this is over a wide area, it becomes impossible.. The squamous cell lung cancer in many patients tends to spread to other tissues including kidney or bone. Suppose, if it spreads to bones, most of the times, mandible or skull may get affected and in such cases increased density with occurrence of periosteal new bones may be noticed.. Squamous cell lung cancer at times need confirmation from ...
Non‑small cell lung cancer (NSCLC) constitutes the majority of all lung‑cancer cases. Aquaporin 5 (AQP5) may be involved in NSCLC by promoting lung‑cancer initiation and progression. The present study aimed to determine the role of AQP5 in migration and angiogenesis using NSCLC cells and HUVECs. AQPs 1, 3, 4, 5, 8 and 9 were screened in the NSCLC cell line H1299, and the present results showed that AQP5 mRNA was upregulated compared with the other AQP genes. At the protein level, AQP5 was significantly increased in H1299 cells compared with 16HBE cells. AQP5 knockdown in H1299 cells significantly decreased cell migration compared with untransfected cells, as demonstrated by both Transwell and wound closure assays. The present study further investigated H1299 ability to promote HUVEC vascularisation. The supernatants of both transfected and untransfected H1299 cells were used as conditioned medium for HUVECs, and tube formation was measured. The supernatant of AQP5‑downregulated cells ...
In an interview with SurvivorNet, Dr. Ronald Natale discussed current clinical trials testing drug Tagrisso on early stage lung cancer patients. While findings have been historic, there is still controversy surrounding how this drug impacts overall survivor rate.
BackgroundStereotactic body radiotherapy (SBRT) demonstrates excellent local control in early stage lung cancer, however a quarter of patients develop recurrence or distant metastasis. Transforming growth factor-beta (TGF-β) supports metastasis and treatment resistance, and angiote...
TY - JOUR. T1 - Mutational analysis of multiple lung cancers. T2 - Discrimination between primary and metastatic lung cancers by genomic profile. AU - Goto, Taichiro. AU - Hirotsu, Yosuke. AU - Mochizuki, Hitoshi. AU - Nakagomi, Takahiro. AU - Shikata, Daichi. AU - Yokoyama, Yujiro. AU - Oyama, Toshio. AU - Amemiya, Kenji. AU - Okimoto, Kenichiro. AU - Omata, Masao. PY - 2017/1/1. Y1 - 2017/1/1. N2 - In cases of multiple lung cancers, individual tumors may represent either a primary lung cancer or both primary and metastatic lung cancers. Treatment selection varies depending on such features, and this discrimination is critically important in predicting prognosis. The present study was undertaken to determine the efficacy and validity of mutation analysis as a means of determining whether multiple lung cancers are primary or metastatic in nature. The study involved 12 patients who underwent surgery in our department for multiple lung cancers between July 2014 and March 2016. Tumor cells were ...
Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor. Clinical trials have reported its effectiveness in the treatment of brain metastases from non-small cell lung cancer by overcoming the blood-brain barrier. Gefitinib is generally regarded as a relatively safe agent, and several reports have described its efficacy in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and a poor performance status. We herein described two patients with brain metastasis from non-small cell lung cancer who achieved the total regression of metastasis with the administration of gefitinib. A 70-year-old Japanese woman was referred to our hospital with a severe cough. Brain magnetic resonance imaging revealed a metastatic lesion in the left temporal lobe. The tumor was positive for an epidermal growth factor receptor L858R mutation in exon 21 using the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp method. She was treated with 250 mg
The Small Cell Lung Cancer Treatment Market is driven by the launch of premium-priced therapies, including anti-PD-1 and anti-CTLA-4 immunotherapies and targeted agents. The market growth is estimated to occur across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan.. Browse Detailed Toc, Tables, Figures, Charts and Companies Mentioned in Small Cell Lung Cancer Treatment Market ResearchReport at- http://www.absolutereports.com/opportunityanalyzer-small-cell-lung-cancer-sclc-opportunity-analysis-and-forecasts-to-2024-10112598. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor Yervoy will be the first immunotherapy to be introduced in the market. This drug is being developed by Bristol-Myers Squibb and will be launched in 2016 across the seven major markets.. The increase in rates of the disease across the five European markets and Japan, at a CAGR of 1.49% over the forecast period is estimated to further bolster the Small Cell Lung Cancer treatment ...
This phase I trial studies the best dose of radiation therapy in treating patients with locally advanced non-small cell lung cancer that cannot be removed by surgery. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy, such as stereotactic body radiation therapy (SBRT), that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. SBRT has been shown to provide excellent results when used in early stage lung cancer, but has not yet been applied to patients with more advanced disease ...
Since 2000, the WHPP Early Lung Cancer Detection (ELCD) Program has provided low-dose chest CT scans to U.S. Department of Energy (DOE) workers, with the primary purpose of detecting lung cancers early. The WHPP ELCD Program serves DOE workers from nine sites in the DOE complex: Idaho National Laboratory (INL); the K-25, Paducah and Portsmouth gaseous diffusion plants (GDPs); the Mound and Fernald closure sites; the Nevada National Security Site (formerly the Nevada Test Site); Oak Ridge National Laboratory; and Y-12. As of September 2015, over 13,000 DOE workers have received low-dose screening CT scans through the ELCD Program; 136 lung cancers have been detected, with the majority (71%) found in early stages.. WHPP participants with an elevated risk of lung cancer based on age, smoking and work history are currently offered annual screening, as well as interim follow-up CT scans, if needed.. A low-dose screening CT scan of the chest uses much less radiation than a standard, full-dose CT scan ...
An increasing number of chromosomal aberrations is being identified in solid tumors providing novel biomarkers for various types of cancer and new insights into the mechanisms of carcinogenesis. We applied next generation sequencing technique to analyze the transcriptome of the non-small cell lung carcinoma (NSCLC) cell line H2228 and discovered a fusion transcript composed of multiple exons of ALK (anaplastic lymphoma receptor tyrosine kinase) and PTPN3 (protein tyrosine phosphatase, nonreceptor Type 3). Detailed analysis of the genomic structure revealed that a portion of genomic region encompassing Exons 10 and 11 of ALK has been translocated into the intronic region between Exons 2 and 3 of PTPN3. The key net result appears to be the null mutation of one allele of PTPN3, a gene with tumor suppressor activity. Consistently, ectopic expression of PTPN3 in NSCLC cell lines led to inhibition of colony formation. Our study confirms the utility of next generation sequencing as a tool for the ...
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) have recently been described in patients with non-small-cell lung cancer (NSCLC) who achieve radiographic regressions to the EGFR inhibitor gefitinib. One of these mutations, L858R (Leu→Arg), is also found in NSCLC cell line H3255, which is very sensitive to gefitinib treatment. We characterized nine NSCLC cell lines (three isolated from patients with bronchioloalveolar carcinoma and six isolated from patients with adenocarcinoma) for their in vitro sensitivity to gefitinib. Of these, only H3255 (EGFRL858R) and H1666 (EGFRWT) are sensitive to gefitinib with IC50 values of 40 nmol/L and 2 μmol/L, respectively. We examined the effects of gefitinib on H3255 and cell lines containing wild-type EGFR that are either sensitive (H1666) or resistant (A549 and H441) to gefitinib exposure in vitro. Gefitinib treatment (1 μmol/L) leads to significant apoptosis accompanied by increased poly(ADP-ribose) ...
[130 Pages Report] Check for Discount on United States Non Small Cell Lung Cancer Therapeutics Industry 2016 Market Research Report report by QYResearch Group. The United States Non Small Cell Lung Cancer Therapeutics Industry...
Lung cancer remains the most frequent cause of cancer death in both men and women in the world. Surgical resection using lobectomy with mediastinal lymph node dissection or sampling has been a standard of care for operable early stage NSCLC. Several studies have reported high local control and survival using SBRT in stage I NSCLC patients. SBRT is now an accepted treatment for medically inoperable patients with stage I NSCLC and patients with operable stage I lung cancer are entered on clinical protocols. The purpose of this study is to conduct a phase III randomized study to compare CyberKnife SBRT with surgery, the current standard of care for stage I operable NSCLC ...
Doctor answers on Symptoms, Diagnosis, Treatment, and More: Dr. Wright on life chances with non small cell lung cancer: Stage 1 nsclc; surgical resection, appr70%5yrsurv stage2nsclc;surgery apprx. 30-35% 5 yr survival. for topic: Life Chances With Non Small Cell Lung Cancer
Between 1990 and 2011, almost 720,000 people were diagnosed with lung cancer. During this time, the number of male lung cancer diagnoses declined, whereas the number of female lung cancer diagnoses increased. Lung cancer incidence increases sharply after middle age. More than 75% of lung cancers are diagnosed in people over the age of 65. The difference in the trends of lung cancer incidence among men and women is even more pronounced when age is taken into account. The sharp decrease in the incidence of male lung cancer over the past two decades reflects the decline in smoking prevalence among men. However, due to the rise in women who took up smoking after World War II, the incidence among women continues to increase. The difference in smoking prevalence between men and women has given rise to a dramatic change in the male to female lung cancer incidence ratio from 3:1 in 1990 to 3:2 in 2011.. ...
For patients with Stage III non-small cell lung cancer, prophylactic (preventive) radiation therapy to the brain reduces the risk of brain metastases but carries a risk of memory problems and doesnt appear to improve overall survival. These results were published in the Journal of Clinical Oncology.. Lung cancer remains the leading cause of cancer death in the United States. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers.. One of the sites to which NSCLC can spread (metastasize) is the brain. Brain metastases can have a profound effect on survival and quality of life.. Prophylactic cranial irradiation (PCI) refers to the administration of radiation to the brain before brain metastases become apparent. The goal of PCI is the prevention of brain metastases. Previous studies have suggested that PCI can reduce the occurrence of brain metastases, but PCI has not become a part of routine NSCLC care because of concern about side effects and lack of evidence that ...
Objective: Lung cancer is the leading cause of cancer-related mortality worldwide. Disease stage still remains the best prognostic factor for patients with localized non-small cell lung cancer. The TNM staging system, however, does not address the heterogeneity of this disease. Sub-classification and identification of distinct prognostic sub-groups within each stage may allow the optimization of clinical trial design and potentially improve outcome. This is a retrospective pilot study, in which we attempt to identify genomic biomarkers predictive of recurrence in stage I lung cancer by analysing copy number (CN) data obtained by next-generation sequencing. Materials and Methods: Ninety eight patients with stage I NSCLC, who underwent elective radical surgery were identified from a tissue bank of 323 tumour samples. Their demographic and surgical data, including their recurrence status were collected and an extensive database compiled. The cases were split into two cohorts depending on their ...
TY - JOUR. T1 - Inactivation of LLC1 gene in nonsmall cell lung cancer. AU - Hong, Kyeong Man. AU - Yang, Sei Hoon. AU - Chowdhuri, Sinchita Roy. AU - Player, Audrey. AU - Hames, Megan. AU - Fukuoka, Junya. AU - Meerzaman, Daoud. AU - Dracheva, Tatiana. AU - Sun, Zhifu. AU - Yang, Ping. AU - Jen, Jin. PY - 2007/6/1. Y1 - 2007/6/1. N2 - Serial analysis of gene expression studies led us to identify a previously unknown gene, c20orf85, that is present in the normal lung epithelium but absent or downregulated in most primary non-small cell lung cancers and lung cancer cell lines. We named this gene LLC1 for Low in Lung Cancer 1. LLC1 is located on chromosome 20q13.3 and has a 70% GC content in the promoter region. It has 4 exons and encodes a protein containing 137 amino acids. By in situ hybridization, we observed that LLC1 message is localized in normal lung bronchial epithelial cells but absent in 13 of 14 lung adenocarcinoma and 9 out of 10 lung squamous carcinoma samples. Methylation at CpG ...
Non-small cell lung cancer is the most common type of lung cancer. About 85% of lung cancers are non-small cell lung cancers. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of non-small cell lung cancer.
Non-small cell lung cancer is the most common type of lung cancer. About 85% of lung cancers are non-small cell lung cancers. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of non-small cell lung cancer.
Disorders of cell adhesion are critical steps in cancer progression in which varieties of markers including cadherins are involved in.Btbd7 was found to inhibit E-cadherin expression in MDCK cells and play important roles during branching morphogenesis of embryonic salivary glands and lungs. However its function in malignant tumors is largely unknown. The aim of this study is to investigate the clinicopathological significance and possible function of Btbd7 in non-small cell lung cancer. Immunohistochemistry and Western blotting were used to investigate Btbd7 expression in non-small cell lung cancer and lung tissues. The clinicopathological association and the overall survival was analyzed. In vitro experiments were performed using siRNA to investigate the function of Btbd7 in lung cancer cells. Btbd7 expression was elevated in non-small cell lung cancer tissues compared to normal lung tissues. Increased Btbd7 expression was significantly associated with lymph node metastasis, reduced E-cadherin
The purpose of this study is to find out if adding the study drug, nivolumab, after surgery and chemotherapy will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the bodys immune system to attack any cancer cells that may remain after surgery.
Metastatic lung cancer survival rate is very low. This kind of lung cancer can prolong life but only for minimal months. It is a stage that involves cancer
TY - JOUR. T1 - Comparison study of quality of life in advanced lung cancer patients on tyrosine kinase inhibitor and platinum doublet chemotherapy. AU - Udupa, K.. AU - Rajendranath, R.. AU - Sagar, T. G.. PY - 2017/1/1. Y1 - 2017/1/1. N2 - INTRODUCTION: Lung cancer is most common cause of cancer death in the world. Most of the patient are diagnosed in the late stages and receive only palliative treatment. The main objective of the palliative chemotherapy is to improve survival as well as the quality of life (QOL). QOL is the most neglected dimension of cancer care in developing countries like India. Palliative chemotherapeutic agent which has minimum toxicity and prolongs the survival of metastatic cancer patients is the need of the day. MATERIALS AND METHODS: In this study, 43 metastatic adenocarcinoma of lung patients of South Indian origin were enrolled. Twenty patients out of this 43 were epidermal growth factor receptor (EGFR) mutation positive and were started on tyrosine kinase ...
Data & statistics on Lung cancer mortality by ethnic group age group and sex: Lung cancer mortality, by ethnic group, age group and sex, 2011, Lung Cancer Mortality Rates by Sex and Ethnicity 1987-1995 Age-adjusted lung cancer mortality rates by sex and ethnicity for the combined period 1990 through 1995, along with their 95% confidence intervals and the rate ratios of each group compared to White rates, are shown in Table 21. (See also Figures 6 and 7, pp. 28-29) Table 21: Lung Cancer Mortality Rates and Rate Ratios by Ethnicity and Sex, ..., That the lung cancer mortality rates in North Denver women were higher than rates in the remainder of the Metro area in all race/ethnicity groups; the differences were statistically significant for all races combined, and white non-Hispanics. For males, lung cancer mortality rates in North Denver were higher than other Metro area rates for all races combined, white non-Hispanics, and Hispanics, but ......
TY - JOUR. T1 - XPC mRNA level may predict relapse in never-smokers with non-small cell lung cancers. AU - Yeh, Kun Tu. AU - Wu, Yi Hui. AU - Lee, Ming Ching. AU - Wang, Lee. AU - Li, Chien Te. AU - Chen, Chih Yi. AU - Lee, Huei. PY - 2012/3. Y1 - 2012/3. N2 - Background. Disease recurrence and distant metastasis are the major causes of death in resected non-small cell lung cancer (NSCLC). The prognostic marker for never-smokers with this disease remains to be identified. To improve patient outcome, establishing an adjacent molecular marker to predict relapse of NSCLC in never-smokers is needed. Methods. Three hundred two lung tumors from NSCLC patients and normal lung tissues from 68 noncancer subjects were enrolled to evaluate XPC (xeroderma pigmentosum group C) mRNA expression by quantitative real-time reverse transcriptase polymerase chain reaction. Receiver operating characteristic curve analysis was used to search for a feasible cutoff point of XPC mRNA levels for predicting ...
Lung cancer remains the major cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) account for at least 80% of all lung tumors and about 30% of them present with unresectable locally advanced disease at diagnosis (stage IIIA-IIIB) [1]. Until the mid 1980s standard treatment of patients with inoperable locally advanced NSCLC consisted of radiotherapy (RT) alone with a median survival time of 10 months[1]. From data about lung cancer population diagnosed in the second half of 1990s, overall survival at one and two years was estimated of 36% and 12% respectively[2].. Rates at 2 and 5 years of 15% and 5% respectively [3]. In attempts to improve the survival in these patients, chemotherapy was added to external beam irradiation. Several trials have been positive in favour of combined therapy [4-6]. More recently, other clinical trials have shown that, in selected patients (good performance status, age ≤ 75 years and minimal weight loss) concomitant platinum-based ...
Inactivation of the p16 and ESR1 tumor suppressor genes by promoter lesion methylation has been reported in many tumor types, including lung cancer. We examined the blood of 95 non-small cell lung cancer patients (66 cases of adenocarcinoma, 23 of squamous cell carcinoma and 6 of large cell carcinoma) and 30 controls consisting of normal subjects and benign disease patients to determine the methylation ratios of p16 and ESR1 using real-time PCR. For both genes, there was a statistically significant difference in the methylation ratio between non-small cell lung cancer patients and controls (p16; ...
TY - JOUR. T1 - Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma. AU - Improta, Giuseppina. AU - Zupa, Angela. AU - Natalicchio, Maria Iole. AU - Sisinni, Lorenza. AU - Marinaccio, Anna. AU - Bozza, Giovanni. AU - Vita, Giulia. AU - Aieta, Michele. AU - Landriscina, Matteo. PY - 2018/1/31. Y1 - 2018/1/31. N2 - Exons 19-21 EGFR activating mutations are predictive biomarkers of response to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). However, uncommon exon 19 EGFR mutations, due to their low frequency, have an uncertain biological and clinical significance and very little is known about their TKI sensitivity. This study was designed to describe the TKI sensitivity of a small cohort of lung adenocarcinomas bearing uncommon exon 19 mutations and to evaluate in silico the correlation between frame-shift exon 19 mutations and EGFR sequence/structure modification. Among 1168 NSCLCs screened for ...
TY - JOUR. T1 - Predictors of primary lung cancer in a solitary pulmonary lesion after a previous malignancy. AU - Nakadate, Akie. AU - Nakadate, Masashi. AU - Sato, Yasunori. AU - Nakagawa, Tassei. AU - Yoshida, Katsuya. AU - Suzuki, Yoshio. AU - Yoshida, Yukihiro. PY - 2017/12/1. Y1 - 2017/12/1. N2 - Objective: A solitary pulmonary lesion in patients with a history of malignancy may be either primary lung cancer or a metastatic lung tumor or benign nodule. We retrospectively examined the preoperative predictive factors for determining the type of pathology. Methods: We used an exact logistic regression analysis to identify radiological and clinical predictors of primary lung cancer. The study included 187 patients who underwent pulmonary resection for a solitary pulmonary lesion and had received previous treatment for a malignancy. Results: There were 107 patients with primary lung cancer, 74 with metastatic lung tumors, and 6 with benign lesions. The previous malignancy included colorectal ...
All information about the latest scientific publications of the Clínica Universidad de Navarra. Survival of Patients with Stage I Lung Cancer Detected on CT Screening
Effects of interferons and tumour necrosis factor-a on human lung cancer cell lines and the development of an interferon-resistant lung cancer cell line. ...
1. Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. Adv Exp Med Biol. 2016;893:1-19 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7-30 3. Lim SM, Syn NL, Cho BC, Soo RA. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Treat Rev. 2018;65:1-10 4. Yue J, Lv D, Wang C, Li L, Zhao Q, Chen H. et al. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin beta3. Oncogene. 2018;37:4300-12 5. Dragnev K, You M Fau - Wang Y, Wang Y Fau - Lubet R, Lubet R. Lung cancer chemoprevention: difficulties, promise and potential agents?. Expert Opin Investig Drugs. 2013;22:35-47 6. Li Q, Zhang D, Chen X, He L, Li T, Xu X. et al. Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer. Scientific reports. 2015;5:16082 7. Tang J, Guo F, Du Y, Liu X, Qin Q, Liu X. et al. Continuous ...
Although the following paper was published already 7 months ago (January 2010, in the British Medical Journal), and is no longer new news, I strongly feel that the information needs to be reinforced.. The authors conducted a review of 10 high-quality studies that evaluated the potential influence on survival in patients with lung cancer who quit smoking after their diagnosis. Most of the studies (9 out of 10) looked only at the effects of smoking in cessation in patients with early stage lung cancers.. What they found was quite remarkable: survival rates doubled among those patients who quit smoking after their diagnosis! In patients with early stage, non-small cell lung cancers, the 5-year survival rates were 33% vs. 70%, in smokers and non-smokers, respectively. In patients with limited stage small cell lung cancer, the 5-year survival rates were 29% vs. 63%, in smokers and non-smokers, respectively.. The authors concluded from their analysis that the doubling of survival was most likely due ...
During this years AACR Annual Meeting we spoke to Dr. Delphine Lissa and Dr. Ana Robles from the National Cancer Institute to learn more about the teams most recent study on the use of two specific biomarkers for risk stratification of stage I lung cancer patients.
San Antonio (TX), Bolton (MA). As originally published in International Clinical Trials, May 2015 - View PDF. In the fight against non-small cell lung cancer, all eyes have been on computed tomography imaging to aid early detection. But advances in the field are leading the oncology and radiology communities to consider novel measurement parameters and techniques to better assess tumour response.. Lung Cancer: Lung cancer is the leading cause of cancer death across the globe, claiming more lives than the next three most common cancers combined (colon, breast and pancreatic). In 2012, the estimate for new cases of lung cancer reached 226,160, with 164,770 deaths accounting for 27% of all cancer deaths. The five-year survival rate is low at 16%, often due to most patients having advanced disease at the time of presentation.. Non-small cell lung cancer (NSCLC) accounts for some 85% of lung cancer diagnoses. Fortunately for this subset of patients, surgery can often be curative, but only if ...
TY - JOUR. T1 - Circulating plasma DNA in non-small cell lung cancer patients is not influenced by inflammatory pulmonary conditions. AU - van der Drift, M.A.. AU - Hol, B.E.A.. AU - Klaassen, C.D.. AU - Prinsen, C.. AU - van Aarssen, Y.A.W.G.. AU - Dekhuijzen, P.N.R.. AU - van der Stappen, J.W.J.. AU - Thunnissen, F.B.J.M.. PY - 2009. Y1 - 2009. M3 - Article. VL - 4. SP - S903-S903. JO - Journal of Thoracic Oncology. JF - Journal of Thoracic Oncology. SN - 1556-0864. IS - 9. ER - ...
Objective: To report the median survival time in a contemporary cohort of dogs with primary lung tumors and intrathoracic nodal metastasis.Design: Retrospective Case Series.Animals (or sample): Dogs with primary lung tumors treated with lung lobectomy and lymph node biopsy.Procedures: The medical record database at Colorado State University was queried for dogs with primary lung tumors from January 1, 2005 to December 31, 2017. Patients were identified for inclusion if they had lung lobectomy and an intrathoracic lymph node biopsy performed. The median survival time (MST) for lymph node positive (LN+) and negative dogs (LN-) was calculated as well as the MST in dogs that did or did not receive adjuvant chemotherapy. Differences were compared between groups with significance set at p Results: The MST in LN+ dogs (n = 11) was 167 days which was not statistically different from LN- dogs (n = 29) at 456 days (p = 0.2407). No significant difference in the MST in LN+ dogs was identified between dogs that
TY - JOUR. T1 - MicroRNAs in non-small cell lung cancer. T2 - Gene regulation, impact on cancer cellular processes, and therapeutic potential. AU - Petrek, Hannah. AU - Yu, Ai Ming. PY - 2019/12/1. Y1 - 2019/12/1. N2 - Lung cancer remains the most lethal cancer among men and women in the United States and worldwide. The majority of lung cancer cases are classified as non-small cell lung cancer (NSCLC). Developing new therapeutics on the basis of better understanding of NSCLC biology is critical to improve the treatment of NSCLC. MicroRNAs (miRNAs or miRs) are a superfamily of genome-derived, small noncoding RNAs that govern posttranscriptional gene expression in cells. Functional miRNAs are commonly dysregulated in NSCLC, caused by genomic deletion, methylation, or altered processing, which may lead to the changes of many cancer-related pathways and processes, such as growth and death signaling, metabolism, angiogenesis, cell cycle, and epithelial to mesenchymal transition, as well as ...
Hello - My husband is a 33 year old non smoker and has been diagnosed with non small cell lung cancer in March 2012. He was not feeling well for a few months with a dry cough which turned into flu like symptoms. His PCP prescribed numerous meds and thought he had pneumonia. He came home from work one night and was complaining of blurred vision, fever & chills. I took him to the ER and he was admitted. The following morning he met with a pulmonary doctor who performed a bronchoscopy. From here, we were told that my husband had mold in his lungs. He was placed on medication for this. A month later he had a follow up with his doctor who informed him that mold was NOT in his lungs. My husband was sent for a CT scan & was told the following morning that he had a collapsed right lung. A chest tube was put in immediately & a right lung biopsy was done. This came back as cancer. We went for a second opinion & cancer was confirmed. My husband underwent a few surgical procedures & has 2 tumors in his ...
Effect of Ape1/Ref-1 on injury caused by stereotactic ablative radiotherapy in the treatment of early stage non-small cell lung cancer, Lei Han, Renzhi Yu, Xin Ni, Zenglei Zhang
Lung cancer is the leading cause of cancer-related mortality. Therapies against non-small cell lung cancer (NSCLC) are particularly needed, as this type of cancer is relatively insensitive to chemotherapy and radiation therapy. We recently identified GGTI compounds that are designed to block geranylgeranylation and membrane association of signaling proteins including the Rho family G-proteins. One of the GGTIs is P61A6 which inhibits proliferation of human cancer cells, causes cell cycle effects with G1 accumulation and exhibits tumor-suppressing effects with human pancreatic cancer xenografts. In this paper, we investigated effects of P61A6 on non-small cell lung cancer (NSCLC) cells in vitro and in vivo. Three non-small cell lung cancer cell lines were used to test the ability of P61A6 to inhibit cell proliferation. Further characterization involved analyses of geranylgeranylation, membrane association and activation of RhoA, and anchorage-dependent and -independent growth, as well as cell cycle
Management of local recurrences and regional failure in early stage non-small cell lung cancer after stereotactic body radiation therapy
TY - JOUR. T1 - Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma. AU - Gjerstorff, Morten F. AU - Pøhl, Mette. AU - Olsen, Karen E. AU - Ditzel, Henrik J. PY - 2013. Y1 - 2013. N2 - The unique expression pattern and immunogenic properties of cancer/testis antigens make them ideal targets for immunotherapy of cancer. The MAGE-A3 cancer/testis antigen is frequently expressed in non-small cell lung cancer (NSCLC) and vaccination with MAGE-A3 in patients with MAGE-A3-positive NSCLC has shown promising results. However, little is known about the expression of other cancer/testis antigens in NSCLC. In the present study the expression of cancer/testis antigens GAGE, NY-ESO-1 and SP17 was investigated in patients with completely resected, early stage, primary NSCLC.. AB - The unique expression pattern and immunogenic properties of cancer/testis antigens make them ideal targets for immunotherapy of cancer. The MAGE-A3 cancer/testis antigen ...
TY - JOUR. T1 - Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer. T2 - Preliminary results comparing sequential phase II trials. AU - DeVore, R. F.. AU - Jagasia, M.. AU - Johnson, D. H.. PY - 1997/10/22. Y1 - 1997/10/22. N2 - Our group previously described the activity of carboplatin plus paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) (given as a 24-hour infusion) in 51 patients with advanced non-small cell lung cancer. To facilitate outpatient administration, the regimen was modified to infuse paclitaxel over 1 hour. Between February 1995 and August 1996, 63 patients with advanced non-small cell lung cancer were accrued by the Vanderbilt Cancer Center and its affiliate network. The first four patients received paclitaxel 175 mg/ml2; all subsequent patients received paclitaxel 200 mg/m2. The carboplatin dose was determined using the Calvert formula, with a target area under the concentration-time curve of 6. ...
TY - JOUR. T1 - Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer. T2 - The eastern cooperative oncology group results. AU - Chang, A. Y.. AU - Kim, K.. AU - Glick, J.. AU - Anderson, T.. AU - Karp, D.. AU - Johnson, D.. PY - 1993/3/3. Y1 - 1993/3/3. N2 - Background: Patients with metastatic (stage IV) non-small-cell lung cancer usually have a poor prognosis and disease refractory to chemotherapy. Three new agents-taxol, merbarone, and piroxantrone-have shown promising antitumor treatment in vitro and in animals. Taxol is an antimicrotubular agent that interferes with mitosis during cell division. Merbarone, a conjugate of thiobarbituric acid and aniline, is a topoisomerase II inhibitor, which thus inhibits DNA synthesis and tumor growth. Piroxantrone, an anthracenedione derivative, is a DNA intercalating agent that has shown potent antitumor activity in animal studies. Purpose: Our randomized phase II study was designed to evaluate the efficacy and ...
RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Giving sorafenib together with erlotinib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving sorafenib together with erlotinib works in treating patients with stage IIIB or stage IV non-small cell lung cancer that has not responded to chemotherapy.
TY - JOUR. T1 - Use of MicroRNA expression levels to predict outcomes in resected stage i non-small cell lung cancer. AU - Duncavage, Eric. AU - Goodgame, Boone. AU - Sezhiyan, Ananth. AU - Govindan, Ramaswamy. AU - Pfeifer, John. PY - 2010/11. Y1 - 2010/11. N2 - Background: Despite undergoing curative resection, nearly a third of patients with stage I non-small cell lung cancer (NSCLC) die of recurrent disease. There are no reliable clinical or molecular predictors of relapse in patients with resected stage I NSCLC. Identifying patients at risk for relapse after surgical resection is one of the important challenges today. MicroRNAs (miRNAs) regulate hundreds of genes central to maintaining a cancer phenotype. Methods: In an exploratory study, we determined whether expression of six miRNAs (let-7a, miR-7, miR-21, miR-155, miR-210, and miR-221) previously reported to correlate with invasiveness or outcome in various human malignancies were associated with tumor recurrence in patients with ...
Ionic channel activity is involved in fundamental cellular behaviour and participates in cancerous features such as proliferation, migration and invasion which in turn contribute to the metastatic process. In this study, we investigated the expression and role of voltage-gated sodium channels in non-small-cell lung cancer cell lines. Functional voltage-gated sodium channels expression was investigated in normal and non-small-cell lung cancer cell lines. The measurement, in patch-clamp conditions, of tetrodotoxin-inhibitable sodium currents indicated that the strongly metastatic cancerous cell lines H23, H460 and Calu-1 possess functional sodium channels while normal and weakly metastatic cell lines do not. While all the cell lines expressed mRNA for numerous sodium channel isoforms, only H23, H460 and Calu-1 cells had a 250 kDa protein corresponding to the functional channel. The other cell lines also had another protein of 230 kDa which is not addressed to the membrane and might act as a dominant
PURPOSE OF REVIEW: The first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, are effective as first-line treatment of advanced nonsmall cell lung cancer (NSCLC) harboring activating EGFR mutations (deletions in exon 19 and exon 21 L858R mutation). EGFR T790 M resistance mutation (EGFR T790 M) ultimately emerged in most of these patients. The second and third-generation EGFR-TKIs were designed to have more potent inhibition of EGFR and to overcome EGFR T790 M. This review describes the recent developments of these novel EGFR-TKIs.. RECENT FINDINGS: The second-generation EGFR-TKIs, afatinib and dacomitinib, irreversibly bind to the tyrosine kinase of EGFR and other ErbB-family members. Afatinib has been approved as first-line treatment of advanced NSCLC harboring activating EGFR mutations. Dacomitinib is under development. Third-generation EGFR-TKIs, AZD9291, CO-1686, and HM61713, inhibit both EGFR activating and resistance mutations, ...
Nieder, Carsten; Andratschke, Nicolaus H; Guckenberger, Matthias (2015). A pooled analysis of stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small cell lung cancer: is failure to recruit patients into randomized trials also an answer to the research question? Annals of Translational Medicine, 3(11):148-151. ...
This phase II trial is studying how well erlotinib works in treating patients with advanced primary non-small cell lung cancer. Erlotinib may stop the g
Objective: To explore the effect of Ape1/Ref-1 on injury caused by stereotactic ablative radiotherapy in the treatment of early stage non-small cell l..
BioAssay record AID 81529 submitted by ChEMBL: Cytotoxicity against NCI tumor panel, HOP-92 non small-cell lung cancer cell line.
This phase II trial is studying how well saracatinib works in treating patients with recurrent, stage IIIB or stage IV non-small cell lung cancer previo
SOTIO presented new statistically and clinically significant results from its Phase I/II clinical trial evaluating DCVAC/LuCa, an active cellular immunotherapy product, in patients with stage IV non-small cell lung cancer. The final analysis of the data confirmed the promising clinical efficacy of DCVAC/LuCa.
Abstract: ABSTRACT Although many mouse models of lung adenocarcinoma exist, there is no mouse lung squamous cell carcinoma model that has been validated for use in preclinical lung cancer chemoprevention studies. Since most clinical chemoprevention trials of lung cancer are performed in subjects with bronchial dysplasia, development of a lung squamous cell carcinoma mouse model becomes one of the highest priorities. We have shown that lung squamous cell carcinomas can be induced chemically in several strains of mice (Wang et al. 2004) and that green tea polyphenols exhibit a significant efficacy against the development of lung squamous cell carcinomas (preliminary data section). In this proposal, we will use a standardized green tea preparation called Polyphenon E (PE) and its major component, EGCG. The overall objective of this proposal is to determine the efficacy of green tea polyphenols in a mouse lung squamous cell carcinoma model and to determine the molecular mechanism that underlies the ...
TY - JOUR. T1 - Inhibitory effect of dihydroaustrasulfone alcohol on the migration of human non-small cell lung carcinoma A549 cells and the antitumor effect on a Lewis lung carcinoma-bearing tumor model in C57BL/6J mice. AU - Chen, Shuo Chueh. AU - Chien, Yi Chung. AU - Pan, Chun Hsu. AU - Sheu, Jyh Horng. AU - Chen, Chih Yi. AU - Wu, Chieh Hsi. PY - 2014/1. Y1 - 2014/1. N2 - There are many major causes of cancer death, including metastasis of cancer. Dihydroaustrasulfone alcohol, which is isolated from marine coral, has shown antioxidant activity, but has not been reported to have an anti-cancer effect. We first discovered that dihydroaustrasulfone alcohol provided a concentration-dependent inhibitory effect on the migration and motility of human non-small cell lung carcinoma (NSCLC) A549 cells by trans-well and wound healing assays. The results of a zymography assay and Western blot showed that dihydroaustrasulfone alcohol suppressed the activities and protein expression of matrix ...
TY - JOUR. T1 - Amurubicinol-induced eotaxin-3 expression in human NCI-H69 small cell lung carcinoma cells. AU - Niiya, Masami. AU - Niiya, Kenji. AU - Shibakura, Misako. AU - Asaumi, Noboru. AU - Yoshida, Chikamasa. AU - Tanimoto, Mitsune. PY - 2006/3. Y1 - 2006/3. N2 - We previously demonstrated the doxorubicin-induced expression of urokinase-type plasminogen activator (uPA), interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-α in human RCK8 lymphoma cells and NCI-H69 small cell lung carcinoma cells in which reactive oxygen species might be involved. Amurubicin hydrochloride (AMR), a novel derivative drug of doxorubicin, was recently introduced to clinical practice for treatment of lung cancer in Japan. Therefore, we investigated the effects of AMR on the expression of uPA and chemokines in NCI-H69 cells. AMR and its active form, amurubicinol hydrochloride (AMROH), both induced the expression of uPA, IL-8 and MCP-1 in H69 cells in a dose-dependent ...
TY - JOUR. T1 - Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations. T2 - The okayama lung cancer study group trial 1001. AU - Ichihara, Eiki. AU - Hotta, Katsuyuki. AU - Nogami, Naoyuki. AU - Kuyama, Shoichi. AU - Kishino, Daizo. AU - Fujii, Masanori. AU - Kozuki, Toshiyuki. AU - Tabata, Masahiro. AU - Harada, Daijiro. AU - Chikamori, Kenichi. AU - Aoe, Keisuke. AU - Ueoka, Hiroshi. AU - Hosokawa, Shinobu. AU - Bessho, Akihiro. AU - Hisamoto-Sato, Akiko. AU - Kubo, Toshio. AU - Oze, Isao. AU - Takigawa, Nagio. AU - Tanimoto, Mitsune. AU - Kiura, Katsuyuki. PY - 2015/3/30. Y1 - 2015/3/30. N2 - Purpose: Whether bevacizumab enhances the effect of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on EGFR mutant non-small cell lung cancers (NSCLCs) remains unknown. We conducted a phase II trial to investigate the efficacy and safety of gefitinib when combined with bevacizumab as ...
Excerpt:. Patients with advanced non-small-cell lung cancer survive four months longer with fewer side effects on an immunotherapy drug called atezolizumab compared to chemotherapy, according to a phase 3 clinical trial published in The Lancet.. The trial enrolled 1225 advanced non-small-cell lung cancer patients who have no more treatment options, but this study used an early analysis of the first 850 patients from the trial. Half of the group were given atezolizumab and the other half were given docetaxel chemotherapy, which is the standard treatment for advanced non-small-cell lung cancer.. Patients given atezolizumab - a drug that blocks the programmed death ligand 1 (PD-L1) protein - survived for an average of 13.8 months, compared with 9.6 months for those on chemotherapy.. Go to full article.. ...
This study compares administration schedules of experimental MPDL3280A (antibody- a protein produced by the bodys immune system) and stereotactic ablative radiotherapy in treating patients with lung cancer. MPDL3280A, may block tumor growth in different ways by targeting certain cells. Stereotactic ablative radiotherapy, is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Giving MPDL3280A with stereotactic ablative radiotherapy may be a better treatment for lung cancer. However, it is not yet known what the best administration schedule is for these treatments. ...
Tumour angiogenesis is an important factor for tumour growth and metastasis. Although some recent reports suggest that microvessel counts in non-small cell lung cancer are related to a poor disease outcome, the results were not conclusive and were not compared with other molecular prognostic markers. In the present study, the vascular grade was assessed in 107 (T1,2-N0,1) operable non-small cell lung carcinomas, using the JC70 monoclonal antibody to CD31. Three vascular grades were defined with appraisal by eye and by Chalkley counting: high (Chalkley score 7-12), medium (5-6), and low (2-4). There was a significant correlation between eye appraisal and Chalkley counting (P | 0.0001). Vascular grade was not related to histology, grade, proliferation index (Ki67), or EGFR or p53 expression. Tumours from younger patients had a higher grade of angiogenesis (P = 0.05). Apart from the vascular grade, none of the other factors examined was statistically related to lymph node metastasis (P | 0.0001). A
A specific, acquired chromosomal abnormality (deletion 3p) has been found in at least one chromosome 3 in 100 percent of the metaphases in 12 of 12 cell lines cultured from human small-cell lung cancer tissue and in 2-day tumor culture specimens from three patients. Analysis of the shortest region of overlap shows the deletion to be 3p(14-23). This specific change was not seen in five of five lung cancer cell lines other than small-cell lung cancer or in two lymphoblastoid lines cultured from cells of small-cell lung cancer patients whose tumors had the 3p deletion. ...